Related references
Note: Only part of the references are listed.Discovery of a PROTAC targeting ALK with in vivo activity
Guoyi Yan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition
Dongchan Kim et al.
ANTICANCER RESEARCH (2020)
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Ning Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction
Xing Qiu et al.
ORGANIC LETTERS (2019)
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai et al.
CANCER CELL (2019)
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
Yangbing Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Chengwei Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Chelsea E. Powell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Satoshi Yoda et al.
CANCER DISCOVERY (2018)
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Chung Hyo Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Erin Larkins et al.
CLINICAL CANCER RESEARCH (2016)
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson et al.
NATURE CHEMICAL BIOLOGY (2015)
ALECTINIB IS ACTIVE IN CRIZOTINIB-RESISTANT ALK-REARRANGED NSCLC
S. M. Gadgeel et al.
CANCER DISCOVERY (2014)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers
Takaaki Sasaki et al.
CLINICAL CANCER RESEARCH (2011)
A mouse model for EML4-ALK-positive lung cancer
Manabu Soda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
